» Articles » PMID: 10366735

OHIO-1 Beta-lactamase Mutants: the Arg244Ser Mutant and Resistance to Beta-lactams and Beta-lactamase Inhibitors

Overview
Specialties Biochemistry
Biophysics
Date 1999 Jun 15
PMID 10366735
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations at residue 244 (Ambler numbering system) in the class A TEM beta-lactamase confer resistance to inactivation by beta-lactamase inhibitors and result in diminished turnover of beta-lactam substrates. The Arg244Ser mutant of the OHIO-1 beta-lactamase, an SHV family enzyme, demonstrates variable susceptibilities to beta-lactamase inhibitors and has significantly reduced catalytic efficiency. The minimum inhibitory concentrations (MICs) for Escherichia coli DH5alpha expressing the Arg244Ser beta-lactamase were reduced when compared to the strain bearing the OHIO-1 beta-lactamase: ampicillin, 512 vs. 8192 micrograms ml-1; cephaloridine, 4 vs. 32 micrograms ml-1, respectively. The MICs for the beta-lactam beta-lactamase inhibitor combinations demonstrated resistance only to ampicillin-clavulanate, 16/8 vs. 8/4 micrograms ml-1 respectively. In contrast, there was increased susceptibility to ampicillin-sulbactam, ampicillin-tazobactam, and piperacillin-tazobactam. When compared to the OHIO-1 beta-lactamase homogenous preparations of the Arg244Ser beta-lactamase enzyme demonstrated increased Km and decreased kcat values for benzylpenicillin (Km=17 vs. 50 microM, kcat=345 vs. 234 s-1) and cephaloridine (Km=97 vs. 202 microM, kcat=1023 vs. 202 s-1). Although the Ki and IC50 values were increased for each inhibitor when compared to OHIO-1 beta-lactamase, the turnover numbers (tn) required for inactivation were increased only for clavulanate. For the Arg244Ser mutant enzyme of OHIO-1, the increased Ki, decreased tn for the sulfones, and different partition ratio (kcat/kinact) support the notion that not all class A enzymes are inactivated in the same manner, and that certain class A beta-lactamase enzymes may react differently with identical substitutions in structurally conserved amino acids. The resistance phenotype of a specific mutations can vary depending on the enzyme.

Citing Articles

Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from .

Nukaga M, Yoon M, Taracilia M, Hoshino T, Becka S, Zeiser E ACS Infect Dis. 2021; 7(4):826-837.

PMID: 33723985 PMC: 8324038. DOI: 10.1021/acsinfecdis.0c00682.


Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam.

Shapiro A Antimicrob Agents Chemother. 2017; 61(12).

PMID: 28971872 PMC: 5700308. DOI: 10.1128/AAC.01612-17.


The importance of the trans-enamine intermediate as a β-lactamase inhibition strategy probed in inhibitor-resistant SHV β-lactamase variants.

Ke W, Rodkey E, Sampson J, Skalweit M, Sheri A, Pagadala S ChemMedChem. 2012; 7(6):1002-8.

PMID: 22438274 PMC: 3523351. DOI: 10.1002/cmdc.201200006.


Three decades of beta-lactamase inhibitors.

Drawz S, Bonomo R Clin Microbiol Rev. 2010; 23(1):160-201.

PMID: 20065329 PMC: 2806661. DOI: 10.1128/CMR.00037-09.


Role of Asp104 in the SHV beta-lactamase.

Bethel C, Hujer A, Hujer K, Thomson J, Ruszczycky M, Anderson V Antimicrob Agents Chemother. 2006; 50(12):4124-31.

PMID: 16982784 PMC: 1694000. DOI: 10.1128/AAC.00848-06.